Published in Int J Colorectal Dis on February 02, 2013
Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome. Tech Coloproctol (2014) 1.02
Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol (2014) 0.82
Irritable bowel syndrome is associated not only with organic but also psychogenic erectile dysfunction. Int J Impot Res (2015) 0.78
Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide. Therap Adv Gastroenterol (2014) 0.76
Irritable bowel syndrome and chronic constipation: Fact and fiction. World J Gastroenterol (2015) 0.75
The Role of H. pylori CagA in Regulating Hormones of Functional Dyspepsia Patients. Gastroenterol Res Pract (2016) 0.75
Neuroendocrine Dysregulation in Irritable Bowel Syndrome Patients: A Pilot Study. J Neurogastroenterol Motil (2017) 0.75
Functional bowel disorders. Gastroenterology (2006) 20.72
Functional bowel disorders and functional abdominal pain. Gut (1999) 7.63
The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther (1997) 5.78
Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology (1988) 4.06
Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology (2004) 4.05
Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology (1997) 2.39
Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology (2006) 2.28
Psychosocial aspects of the functional gastrointestinal disorders. Gut (1999) 1.99
Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol (2000) 1.93
Obsessional-compulsive complaints. Behav Res Ther (1977) 1.92
Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatr Clin North Am (1998) 1.85
Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut (1998) 1.62
Review article: irritable bowel syndrome. Aliment Pharmacol Ther (1997) 1.51
Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics (1993) 1.51
Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol (2006) 1.43
Stress and distress in response to psychosocial stimuli. Laboratory and real life studies on sympathoadrenomedullary and related reactions. Acta Med Scand Suppl (1972) 1.41
Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome. Neurogastroenterol Motil (2008) 1.41
Management of irritable bowel syndrome. Postgrad Med J (2003) 1.40
Increased urine catecholamines and cortisol in women with irritable bowel syndrome. Am J Gastroenterol (1996) 1.33
An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut (2001) 1.26
Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gastroenterology (2003) 1.23
Basal and stimulated hypothalamic-pituitary-adrenal axis activity in patients with functional gastrointestinal disorders and healthy controls. Psychosom Med (2005) 1.18
The sympathetic nervous system modulates perception and reflex responses to gut distention in humans. Gastroenterology (1995) 1.18
Corticotropin releasing hormone in colonic mucosa in patients with ulcerative colitis. Gut (1995) 1.13
Diarrhea- and constipation-predominant IBS patients differ in postprandial autonomic and cortisol responses. Am J Gastroenterol (2001) 1.10
Changes in rectal sensitivity after hypnotherapy in patients with irritable bowel syndrome. Gut (1990) 1.04
Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron. Am J Gastroenterol (2003) 1.04
Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol (2012) 1.03
Autonomic nervous system function in patients with functional abdominal pain. An experimental study. Scand J Gastroenterol (1993) 0.97
Current insights in to the pathophysiology of Irritable Bowel Syndrome. Gut Pathog (2010) 0.94
Autonomic cardiovascular responses are impaired in women with irritable bowel syndrome. J Clin Gastroenterol (2004) 0.92
From cytokines to toll-like receptors and beyond - current knowledge and future research needs in irritable bowel syndrome. J Neurogastroenterol Motil (2010) 0.85
The Rome II and Rome III criteria identify the same subtype-populations in irritable bowel syndrome: agreement depends on the method used for symptom report. Neurogastroenterol Motil (2012) 0.85
Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology (2008) 5.77
Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology (2007) 3.39
Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology (2013) 3.06
Endothelial dysfunction in small arteries of essential hypertensive patients: role of cyclooxygenase-2 in oxidative stress generation. Hypertension (2013) 2.82
The assessment of endothelial function: from research into clinical practice. Circulation (2012) 2.68
Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med (2002) 2.56
Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol (2003) 2.34
Thyroid disorders in chronic hepatitis C. Am J Med (2004) 2.19
An inter- and intra-laboratory comparison of breath ¹³CO₂analysis. Aliment Pharmacol Ther (2003) 2.03
Relationship between wave reflection and renal damage in hypertensive patients: a retrospective analysis. J Hypertens (2013) 1.98
Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine. J Hypertens (2015) 1.97
Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care (2009) 1.91
Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J (2012) 1.91
Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology (2005) 1.81
Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers. Br J Clin Pharmacol (2009) 1.81
Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol (2007) 1.78
Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J (2010) 1.67
The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology (2003) 1.64
Assessment of flow-mediated dilation reproducibility: a nationwide multicenter study. J Hypertens (2012) 1.62
Endothelium-dependent contractions in hypertension. Br J Pharmacol (2005) 1.59
TT virus in the nasal secretions of children with acute respiratory diseases: relations to viremia and disease severity. J Virol (2003) 1.58
Cardiovascular effects of canrenone in patients with preascitic cirrhosis. Hepatology (2002) 1.55
Inter-rater reliability of case-note audit: a systematic review. J Health Serv Res Policy (2007) 1.52
Effect of oral contraceptives on endothelial function in the peripheral microcirculation of healthy women. J Hypertens (2003) 1.49
Physical activity, plasma antioxidant capacity, and endothelium-dependent vasodilation in young and older men. Am J Hypertens (2005) 1.49
Risk factors for Barrett's esophagus: a case-control study. Int J Cancer (2002) 1.49
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press (2005) 1.49
Effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients. Circulation (2009) 1.49
Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension (2003) 1.48
Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. EuroIntervention (2015) 1.47
"PancPro" as a tool for selecting families eligible for pancreatic cancer screening: an Italian study of incident cases. Dig Liver Dis (2012) 1.45
Effect of mild hyperisulinemia on conduit vessel endothelial function: role of noradrenergic activation. J Hypertens (2012) 1.42
Comparison of efficacy of antiplatelet treatments for patients with claudication. A meta-analysis. Thromb Haemost (2010) 1.41
Soluble CD40 ligand is predictive of combined cardiovascular morbidity and mortality in patients on haemodialysis at a relatively short-term follow-up. Nephrol Dial Transplant (2011) 1.40
A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA (2004) 1.40
Tissue-type plasminogen activator release in healthy subjects and hypertensive patients: relationship with beta-adrenergic receptors and the nitric oxide pathway. Hypertension (2008) 1.39
Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am J Hypertens (2007) 1.36
The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J Am Coll Cardiol (2003) 1.33
New treatments compared to established treatments in randomized trials. Cochrane Database Syst Rev (2012) 1.28
Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol (2009) 1.27
Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice. J Hepatol (2006) 1.24
Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor. J Biol Chem (2003) 1.23
Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood (2010) 1.21
The eye and the heart. Eur Heart J (2013) 1.18
Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol (2004) 1.17
Vascular generation of tumor necrosis factor-α reduces nitric oxide availability in small arteries from visceral fat of obese patients. J Am Coll Cardiol (2011) 1.16
Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol (2006) 1.14
Efficacy of Nissen fundoplication versus medical therapy in the regression of low-grade dysplasia in patients with Barrett esophagus: a prospective study. Ann Surg (2006) 1.12
First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Teratol (2003) 1.12
Hydrogen sulphide: novel opportunity for drug discovery. Med Res Rev (2010) 1.11
How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related? World J Gastroenterol (2012) 1.11
Hepatitis C virus (HCV) infection: a systemic disease. Mol Aspects Med (2007) 1.11
Sympathetic regulation of vascular function in health and disease. Front Physiol (2012) 1.07
Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. J Hepatol (2002) 1.07
Radionuclide gastroesophageal motor studies. J Nucl Med (2004) 1.06
Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. Hepatology (2008) 1.06
Hypertension and endothelial dysfunction: therapeutic approach. Curr Vasc Pharmacol (2012) 1.06
Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. World J Gastroenterol (2013) 1.05
Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let's Re-Evaluate Our Priorities. J Am Coll Cardiol (2015) 1.05
Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron. Am J Gastroenterol (2003) 1.04
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. Hepatology (2015) 1.03
Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol (2006) 1.03
Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol (2012) 1.03
Oxidative stress, chronic inflammation, and telomere length in patients with periodontitis. Free Radic Biol Med (2010) 1.02
Cyclooxygenase-1 is involved in endothelial dysfunction of mesenteric small arteries from angiotensin II-infused mice. Hypertension (2006) 1.02
Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. J Pharmacol Exp Ther (2007) 1.01
Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging (2007) 1.01
Gastrointestinal manifestations in myotonic muscular dystrophy. World J Gastroenterol (2006) 1.01
Simple and reliable method for detection and genotyping of hepatitis C virus RNA in dried blood spots stored at room temperature. J Clin Microbiol (2002) 1.01
Vertebroplasty and kyphoplasty: complementary techniques for the treatment of painful osteoporotic vertebral compression fractures. A prospective non-randomised study on 154 patients. Eur Spine J (2009) 1.01
Accuracy of b-GGT fraction for the diagnosis of non-alcoholic fatty liver disease. Liver Int (2011) 1.00
Multiple immune disorders in unrecognized celiac disease: a case report. World J Gastroenterol (2003) 1.00